# Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

> **NCT03155061** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 183 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** ONO-4578
- **DRUG:** ONO-4538

## Key facts

- **NCT ID:** NCT03155061
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-19
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03155061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03155061, "Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03155061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*